新型口服生物制剂治疗炎症性肠病的研究进展

摘要

生物制剂作为近二十年来新兴的治疗药物,对炎症性肠病(IBD)的疗效已得到肯定.然而,目前用于IBD治疗的生物制剂均需静脉滴注或皮下注射,部分制剂需要在严密观察下输注.因而,寻找一种安全、有效的口服生物制剂具有积极的临床意义.本文就近年新型口服生物制剂在I B D治疗中的研究进展作一综述.%As a new therapy in past twenty years,biological agents have been approved for the treatment of inflammatory bowel disease (IBD). However,biological agents currently used for IBD treatment require intravenous or subcutaneous injections,and some require infusion under close observation. Therefore,it is of positive clinical significance to find a safe and effective oral biological agent. This article reviewed recent advances in study on novel oral biological agents in the treatment of IBD.